HENRY SCHEIN, INC.  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued) (In thousands, except per share data) 87 Note 12 – Income Taxes – (Continued) The tax provisions attributable to continuing operations differ from the amount computed using the federal statutory income tax rate as follows:
## Table 0 ##
For the year ended December 25, 2010, our effective tax rate from continuing operations was 31.9% compared to 28.2% for the prior year period.
The difference resulted primarily from the reduction of a valuation allowance in 2009 as explained below.
Without the effect of the reduction of the valuation allowance described below, our effective tax rate from continuing operations for the year ended December 26, 2009 would have been 32.8%.
The net reduction in our 2010 effective tax rate results from additional tax planning initiatives, settlements of tax audits, a reduction of valuation allowances and higher income from lower taxing countries.
The difference between our effective tax rate and the federal statutory tax rate for both periods related primarily to foreign and state income taxes.
During the third quarter of 2009, we substantially completed a plan of reorganization outside the United States that allowed us to utilize tax loss carryforwards to offset taxable income beginning in 2010 in certain foreign tax jurisdictions.
As a result, we determined that it is more likely than not that a portion of deferred tax assets previously fully reserved will be realized.
Therefore, the 2009 provision for income taxes includes a $20.9 million reduction of the valuation allowance which is based on an estimate of future taxable income available to be offset by the tax loss carryforwards.
Provision has not been made for U. S.  or additional foreign taxes on undistributed earnings of foreign subsidiaries, which have been, and will continue to be reinvested.
These earnings could become subject to additional tax if they were remitted as dividends, if foreign earnings were loaned to us or a U. S.  affiliate, or if we should sell our stock in the foreign subsidiaries.
It is not practicable to determine the amount of additional tax, if any, that might be payable on the foreign earnings.
As of December 25, 2010, the cumulative amount of reinvested earnings was approximately $344.0 million.
ASC Topic 740 clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with other provisions contained within this guidance.
This topic prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return.
For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by the taxing authorities.
The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate audit settlement.
2010 Compared to 2009 Net Sales Net sales for 2010 and 2009 were as follows (in thousands):
## Table 1 ##
(1) Consists of consumable products, small equipment, laboratory products, large dental and medical equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
(2) Consists of products sold in the United States and Canadian dental markets.
(3) Consists of products sold in the United States’ medical market.
(4) Consists of products sold in the United States’ animal health market.
(5) Consists of products sold in the dental, medical and animal health markets, primarily in Europe, Australia and New Zealand.
(6) Consists of practice management software and other value-added products and services, which are distributed primarily to healthcare providers in the United States, Canada, the United Kingdom, Australia and New Zealand.
The $988.5 million, or 15.1%, increase in net sales for the year ended December 25, 2010 includes an increase of 15.4% local currency growth (3.1% internally generated revenue and 12.3% growth from acquisitions) offset by a decrease of 0.3% related to foreign currency exchange.
The $168.9 million, or 6.7%, increase in dental net sales for the year ended December 25, 2010 includes a increase of 5.7% in local currencies (2.2% increase in internally generated revenue and 3.5% growth from acquisitions) and an increase of 1.0% related to foreign currency exchange.
The 5.7% increase in local currency sales was due to increases in dental equipment sales and service revenues of 2.5% (2.3% increase in internally generated revenue and 0.2% growth from acquisitions) and dental consumable merchandise sales growth of 6.7% (2.2% increase in internally generated revenue and 4.5% growth from acquisitions).
The $73.4 million, or 6.0%, increase in medical net sales for the year ended December 25, 2010 includes an increase in internally generated revenue of 2.3% and acquisition growth of 3.7%.
The $649.2 million, or 270.4%, increase in animal health net sales for the year ended December 25, 2010 includes acquisition growth of 269.8%, due to the acquisition of a majority interest in Butler Animal Health Supply, LLC as of December 31, 2009, as well as internally generated revenue of 0.6%.
The $70.1 million, or 2.9%, increase in international net sales for the year ended December 25, 2010 includes sales growth of 4.9% in local currencies (4.2% internally generated growth and 0.7% growth from acquisitions) offset by a decrease of 2.0% related to foreign currency exchange.
The $26.7 million, or 15.4%, increase in technology net sales for the year ended December 25, 2010 includes an increase of 14.8% in local currency growth (10.4% internally generated growth and 4.4% growth from acquisitions) and an increase of 0.6% related to foreign currency exchange.
Divestiture of the Information Systems & Global Solutions Business On August 16, 2016, we completed the previously announced divestiture of the IS&GS business, which merged with a subsidiary of Leidos, in a Reverse Morris Trust transaction (the “Transaction”).
The Transaction was completed in a multistep process pursuant to which we initially contributed the IS&GS business to Abacus Innovations Corporation (Abacus), a wholly owned subsidiary of Lockheed Martin created to facilitate the Transaction, and the common stock of Abacus was distributed to participating Lockheed Martin stockholders through an exchange offer.
Under the terms of the exchange offer, Lockheed Martin stockholders had the option to exchange shares of Lockheed Martin common stock for shares of Abacus common stock.
At the conclusion of the exchange offer, all shares of Abacus common stock were exchanged for 9,369,694 shares of Lockheed Martin common stock held by Lockheed Martin stockholders that elected to participate in the exchange.
The shares of Lockheed Martin common stock that were exchanged and accepted were retired, reducing the number of shares of our common stock outstanding by approximately 3%.
Following the exchange offer, Abacus merged with a subsidiary of Leidos, with Abacus continuing as the surviving corporation and a wholly-owned subsidiary of Leidos.
As part of the merger, each share of Abacus common stock was automatically converted into one share of Leidos common stock.
We did not receive any shares of Leidos common stock as part of the Transaction and do not hold any shares of Leidos or Abacus common stock following the Transaction.
Based on an opinion of outside tax counsel, subject to customary qualifications and based on factual representations, the exchange offer and merger will qualify as tax-free transactions to Lockheed Martin and its stockholders, except to the extent that cash was paid to Lockheed Martin stockholders in lieu of fractional shares.
In connection with the Transaction, Abacus borrowed an aggregate principal amount of approximately $1.84 billion under term loan facilities with third party financial institutions, the proceeds of which were used to make a one-time special cash payment of $1.80 billion to Lockheed Martin and to pay associated borrowing fees and expenses.
The entire special cash payment was used to repay debt, pay dividends and repurchase stock during the third and fourth quarters of 2016.
The obligations under the Abacus term loan facilities were guaranteed by Leidos as part of the Transaction.
As a result of the Transaction, we recognized a net gain of approximately $1.2 billion.
The net gain represents the $2.5 billion fair value of the shares of Lockheed Martin common stock exchanged and retired as part of the exchange offer, plus the $1.8 billion one-time special cash payment, less the net book value of the IS&GS business of about $3.0 billion at August 16, 2016 and other adjustments of about $100 million.
The final gain is subject to certain post-closing adjustments, including final working capital, indemnification, and tax adjustments, which we expect to complete in 2017.
We classified the operating results of our IS&GS business as discontinued operations in our consolidated financial statements in accordance with U. S.  GAAP, as the divestiture of this business represented a strategic shift that had a major effect on our operations and financial results.
However, the cash flows generated by the IS&GS business have not been reclassified in our consolidated statements of cash flows as we retained this cash as part of the Transaction.
The carrying amounts of major classes of the IS&GS business assets and liabilities that were classified as assets and liabilities of discontinued operations as of December 31, 2015 are as follows (in millions):
## Table 2 ##

<table><tr><td></td><td colspan="3">Years ended</td></tr><tr><td></td><td>December 25, 2010</td><td>December 26, 2009</td><td>December 27, 2008</td></tr><tr><td>Income tax provision at federal statutory rate</td><td>$175,713</td><td>$158,452</td><td>$138,407</td></tr><tr><td>State income tax provision, net of federal income tax effect</td><td>13,224</td><td>10,078</td><td>9,426</td></tr><tr><td>Foreign income tax benefit</td><td>-17,109</td><td>-16,743</td><td>-11,902</td></tr><tr><td>Valuation allowance</td><td>-7,085</td><td>-19,467</td><td>3,090</td></tr><tr><td>Interest expense related to loans</td><td>-9,714</td><td>-7,014</td><td>-7,254</td></tr><tr><td>Other</td><td>5,040</td><td>2,215</td><td>-557</td></tr><tr><td>Total income tax provision</td><td>$160,069</td><td>$127,521</td><td>$131,210</td></tr></table>
<table><tr><td></td><td></td><td rowspan="2">% of Total</td><td></td><td rowspan="2">% of Total</td><td colspan="2">Increase</td></tr><tr><td></td><td>2010</td><td>2009</td><td>$</td><td>%</td></tr><tr><td>Healthcare distribution -1:</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dental -2</td><td>$2,678,830</td><td>35.6%</td><td>$2,509,921</td><td>38.4%</td><td>$168,909</td><td>6.7%</td></tr><tr><td>Medical -3</td><td>1,290,428</td><td>17.1</td><td>1,217,020</td><td>18.6</td><td>73,408</td><td>6.0</td></tr><tr><td>Animal health -4</td><td>889,303</td><td>11.8</td><td>240,082</td><td>3.7</td><td>649,221</td><td>270.4</td></tr><tr><td>International -5</td><td>2,468,277</td><td>32.8</td><td>2,398,105</td><td>36.7</td><td>70,172</td><td>2.9</td></tr><tr><td>Total healthcare distribution</td><td>7,326,838</td><td>97.3</td><td>6,365,128</td><td>97.4</td><td>961,710</td><td>15.1</td></tr><tr><td>Technology -6</td><td>199,952</td><td>2.7</td><td>173,208</td><td>2.6</td><td>26,744</td><td>15.4</td></tr><tr><td>Total</td><td>$7,526,790</td><td>100.0%</td><td>$6,538,336</td><td>100.0%</td><td>$988,454</td><td>15.1</td></tr></table>
<table><tr><td>Receivables, net</td><td>$807</td></tr><tr><td>Inventories, net</td><td>143</td></tr><tr><td>Other current assets</td><td>19</td></tr><tr><td>Property, plant and equipment, net</td><td>101</td></tr><tr><td>Goodwill</td><td>2,881</td></tr><tr><td>Intangible assets</td><td>125</td></tr><tr><td>Other noncurrent assets</td><td>54</td></tr><tr><td>Total assets of the disposal group</td><td>$4,130</td></tr><tr><td>Accounts payable</td><td>$-229</td></tr><tr><td>Customer advances and amounts in excess of costs incurred</td><td>-285</td></tr><tr><td>Salaries, benefits and payroll taxes</td><td>-209</td></tr><tr><td>Other current liabilities</td><td>-225</td></tr><tr><td>Deferred income taxes</td><td>-145</td></tr><tr><td>Other noncurrent liabilities</td><td>-60</td></tr><tr><td>Total liabilities of the disposal group</td><td>$-1,153</td></tr></table>

Question: What is the growing rate of Other in Table 0 in the year with the most Technology -6 in Table 1?